AdJane

Amplifying The Vaccines Of Tomorrow

AdJane’s novel adjuvant technology

In the world of vaccines, we are revolutionizing the landscape with our innovative adjuvant technology. Our disruptive adjuvant products boost the potential and efficacy of vaccines, addressing critical healthcare challenges by enhancing the immune response. AdJane aims to reshape how vaccines are developed and delivered, providing enhanced protection against various diseases for people around the world.

What is an adjuvant?

An adjuvant is a crucial component of modern vaccines. It is a substance added to a vaccine to amplify the body’s immune response. By boosting the intensity of the response, adjuvants ensure that the immune system can recognize the vaccine’s components more effectively and remember them for longer periods of time, which may lead to a faster, longer-lasting and broader response of the immune system. Overall, the use of adjuvants enables vaccines to induce more persistent and potent immune responses, ensuring broader protection against infectious diseases.

Our unique Ada-24 adjuvant product

At the heart of AdJane’s innovations lies our proprietary Ada-24 adjuvant. Ada-24 is based on and leverages the features of Outer Membrane Vesicles (OMVs), which are spherical nanoparticles that are naturally released by gram-negative bacteria. These spherical particles carry immune potentiators such as Pathogen Associated Molecular Patterns, thus enhancing protective immunity against target antigens when mixed with Ada-24. Unique to this adjuvant is the high detoxification process of the LPS in the OMVs, resulting in an excellent safety profile. Various studies have shown that the inclusion of our proprietary Ada-24 adjuvant significantly boosts the immune response by inducing Th1/Th2/Th17 immunity, outperforming conventional adjuvants. In addition, our proprietary Ada-24 adjuvant can be incorporated efficiently into vaccine concepts  and can be produced in short timelines at high quality, following GMP requirements.  Our Ada-24 adjuvant can be mixed with bacterial or viral antigens, making it highly efficacious.

News

AdJane Announces its Official Launch as a Leader in Vaccine Adjuvants

Delft, Netherlands, October 24, 2024 – AdJane is proud to announce its official launch as a pioneer in the field of vaccine adjuvants, dedicated to enhancing the efficacy of vaccines ...

About us

AdJane aims to reshape how vaccines are developed and delivered, providing enhanced protection against various diseases for people around the world.

Anita Gashi

Director

Marlène Goedvolk

Finance Director